Cost-effectiveness of Ozurdex® in the treatment of macular oedema following Retinal Vein Occlusion.
|12/11/2010||16/12/2010||Full Pharmacoeconomic Evaluation Recommended|
|24/11/2011||16/03/2012||Reimbursement Not Recommended|
We believe that at the submitted price, Ozurdex® cannot be considered cost-effective therapy for the treatment of macular oedema following retinal vein occlusion.
Following resubmission of pricing information the NCPE conclude that Ozurdex® is a cost effective treatment strategy versus observation (base case) in RVO. The ICER for Ozurdex® versus observation is €25,601/QALY (basecase). The probability of cost effectiveness at a threshold of €45,000/QALY is 88.97%.